Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: InvestorLady who wrote (785)	5/8/1998 4:13:00 PM
From: jerry carlson	Respond to of 1491

Lady One of the reasons I invested in PARS was that I have a daughter who suffered a severe head injury. If HU-211 would have been available maybe there wouldn't have been so much brain damage. On the lighter side-- maybe there will be some cash from this company for her future. Life takes us on unexpected branches. As someone new to drug testing and approval process, how long will it take for HU-211 to be on the market? I realize there are many random components to the process even after "successful" advance clinical trials, but maybe someone here can give an educated guess. jerry

To: InvestorLady who wrote (785)	5/8/1998 4:15:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1491

I don't think of the 80 score as a "B." I wouldn't want a surgeon talking about the stock market the whole time he was taking out my appendix and I don't want the scientists working on these important drugs to do it either. I think it's in our best interest to encourage them to be responsive to the investment community, but know that's not an overnight task. I have had a scientist in a biotech incubator as a consulting client and it's not easy to turn the white coat into an Armani suit and make the person glib in financial circles. Nevertheless, PARS has made definite progress in the past few months. It has hired an experienced CFO, put up a decent website, and has a new person dedicated to Investor Relations work. Just as big biotech companies are, in effect, out-sourcing R&D work to small companies like Pharmos, the management of PARS is kind of "out-sourcing" (though obviously "in") the important financial side of the business to professionals with experience in that area. This shows they understand the importance of these functions and also that the training for a scientist does not match this job description. I believe the weaknesses in our financial structure, normal for a biotech-in-the-making, will even out as we get the HU-211 joint partner. Your mentioning the investment risks in PARS as dilution, clinical trial results, and product acceptance made me smile. None are particular to biotech and investing is, after all, a speculative venture. Enjoy the ride, Ariella